[Therapeutic management of systemic sclerosis].

Abstract

UNLABELLED:

Improved understanding of the pathophysiology of systemic sclerosis (SSc) opens new therapeutic avenues in its treatment. The efficacy of disease-modifying agents remains limited however, and none has yet demonstrated its ability to improve survival in a prospective randomized trial.

RESULTS:

of traditional antifibrotic agents such as colchicine and D-penicillamine are disappointing. Cyclophosphamide (CYC) seems to be beneficial in interstitial lung disease associated with SSc. Organ-specific therapies may produce dramatic benefits. Examples include angiotensin-converting enzyme inhibitors for renal failure and epoprostenol for primary pulmonary hypertension. Several new therapeutic approaches are currently under evaluation, including high-dose CYC followed by peripheral stem cell transplantation, vasodilators, and antiinflammatory and antifibrotic agents. Physical therapy and rehabilitation may help to treat disability and loss of function in SSc patients.

• Authors: Luc Mouthon, Alice Berezné, Serge Poiraudeau, Loïc Guillevin
• Journal: Presse medicale (Paris, France : 1983) (Presse Med) Vol. 35 Issue 12 Pt 2 Pg. 1975-82 (Dec 2006) ISSN: 0755-4982 [Print] France
• Vernacular Title: Prise en charge thérapeutique de la sclérodermie systémique.
• PMID: 17159724 (Publication Type: Comparative Study, English Abstract, Journal Article, Review)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors
• Anti-Inflammatory Agents
• Anti-Inflammatory Agents, Non-Steroidal
• Antihypertensive Agents
• Immunosuppressive Agents
• Vasodilator Agents
• Cyclophosphamide
• Interferons
• Epoprostenol
• Penicillamine
• Cysteine
• bucillamine

Topics

• Acute Kidney Injury (drug therapy, etiology)
• Angiotensin-Converting Enzyme Inhibitors (administration & dosage, therapeutic use)
• Anti-Inflammatory Agents (therapeutic use)
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, therapeutic use)
• Antihypertensive Agents (administration & dosage, therapeutic use)
• Cyclophosphamide (administration & dosage, therapeutic use)
• Cysteine (administration & dosage, analogs & derivatives, therapeutic use)
• Epoprostenol (administration & dosage, therapeutic use)
• Humans
• Hypertension, Pulmonary (drug therapy, etiology)
• Immunosuppressive Agents (administration & dosage, therapeutic use)
• Interferons (administration & dosage, therapeutic use)
• Lung Diseases, Interstitial (drug therapy, etiology)
• Orthotic Devices
• Penicillamine (administration & dosage, therapeutic use)
• Peripheral Blood Stem Cell Transplantation
• Physical Therapy Modalities
• Prospective Studies
• Randomized Controlled Trials as Topic
• Retrospective Studies
• Scleroderma, Systemic (complications, drug therapy, mortality, physiopathology, rehabilitation, therapy)
• Vasodilator Agents (therapeutic use)